Pathogenesis and management of antiphospholipid syndrome

Thrombosis Research

Volumn 123, Issue SUPPL. 2, 2009, Pages

  Greaves, Mike ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; PREGNANCY; PREGNANCY OUTCOME; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; THROMBOSIS;

EID: 65549107666     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70002-7     Document Type: Article

References (53)

1. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005 Feb 15; 105(4):1540-5.
2. Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005 Feb 15;105(4):1552-7.
3. Vickers M, Greaves M. The cryptic path from epitope to clot: A story of 2 domains? Blood 2005;105:1371-2.
4. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, et al. Complexes of antiprothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001 Jun;113(3):621-9.
5. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993 Jan; 168(1 Pt 1):206-10.
6. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 Feb;79(2):276-81.
7. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990 Sep; 76(1):101-7.
8. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998 May;112(2):325-33.
9. Atsumi T, Khamashta MA, Andujar C, Leandro MJ, Amengual O, Ames PR, et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998 Jan;25(1):69-73.
10. Patterson AM, Ford I, Graham A, Booth NA, Greaves M. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol 2006 May;133(3):323-30.
11. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007 Sep 1;110(5):1483-91.
12. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, et al. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007 Oct 1;110(7):2423-31.
13. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 Nov; 10(11):1222-6.
14. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007 Feb;196(2):167.e1 167.e5.
15. Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G. Complement activation: A novel pathogenic mechanism in the antiphospholipid syndrome. Ann NY Acad Sci 2005 Jun;1051:413-20.
16. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, et al. Thrombus formation induced by antibodies to beta2- glycoprotein I is complement dependent and requires a priming factor. Blood 2005 Oct 1;106(7):2340-6.
17. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 2006 Jun;12(6):682-7.
18. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb;4(2):295-306.
19. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992 Dec 15;117(12):997-1002.
20. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middleaged men. Circulation 1995 Jan 1;91(1):23-7.
21. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose). Thromb Haemost 1995 Mar;73(3):444-52.
22. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002 Oct; 118(4):548-57.
23. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: An analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997 May;77(5):934-7.
24. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: Performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003 Oct;49(10):1608-14.
25. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE, et al. Lupus anticoagulant testing: Improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002 Nov; 119(2):364-9.
26. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, et al. Inter-laboratory variability of antibeta2- glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002 Jul;88(1):66-73.
27. Favaloro EJ, Wong RC, Jovanovich S, Roberts-Thomson P. A review of beta2-glycoprotein-I antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007 Mar;127(3):441-8.
28. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007; 120(1):127-33.
29. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003 Mar 1;101(5):1827 32.
30. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003 Oct 15;102(8):2717 23.
31. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004 Jul;2(7):1077-81.
32. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N ngl J Med 2003 Sep 18;349(12):1133-8.
33. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J hromb Haemost 2005 May;3(5):848 53.
34. Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997 Sep;98(4):887 92.
35. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001 Dec;115(3):672-8.
36. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998 Apr;104(4):332-8.
37. van Goor MP, Alblas CL, Leebeek FW, Koudstaal PJ, Dippel DW. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand 2004 Jun;109(6):410-5.
38. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. J Am Med Assoc 2004 Feb 4; 291(5):576-84.
39. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis. Lupus 1996 Jun;5(Suppl 1):S16-22.
40. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002 Aug;41(8):924-9.
41. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008 Sep 1; 112(5):1687 95.
42. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006 Feb;33(2):355-7.
43. Ruckert A, Glimm H, Lubbert M, Grullich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: A case with long-term follow-up. Lupus 2008 Aug;17(8):757 60.
44. Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega- Ostertag ME, Harris EN, et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004 Sep;2(9):1558 63.
45. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2- glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001 Dec;44(12):2870-8.
46. Sampietro T, Bigazzi F, Rossi G, Dal Pino B, Puntoni MR, Sbrana F, et al. Upregulation of the immune system in primary hypercholesterolaemia: Effect of atorvastatin therapy. J Intern Med 2005 Jun;257(6):523-30.
47. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van Der Helm Y, Erkelens DW, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: Effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001 Sep; 21(9):1526-30.
48. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007 Jul;56(7):2382-91.
49. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996 May;174(5):1584-9.
50. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997 Jan 25;314(7076):253-7.
51. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 2002 Sep;100(3):408 13.
52. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy a systematic review of randomized therapeutic trials. Thromb Res 2004; 114(5-6):419 26.
53. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicenter prospective study of 1,000 patients. Ann Rheum Dis 2008 Sep 18 (Epub ahead of print).